Darden posts first same-store sales decline since pandemic, offset by Ruth's Chris acquisition

Darden posts first same-store sales decline since pandemic, offset by Ruth's Chris acquisition


A Ruth’s Steak House restaurant on May 03, 2023 in Miami, Florida. Darden Restaurants said Wednesday it is buying Ruth’s Hospitality Group, the parent company of Ruth’s Chris Steak House, for $715 million. 

Joe Raedle | Getty Images

Darden Restaurants on Thursday reported mixed quarterly results as the Olive Garden owner’s same-store sales shrank for the first time since the pandemic.

Shares of the company fell more than 5% in premarket trading.

Here’s what the company reported compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:

  • Earnings per share: $2.62 adjusted, meeting expectations
  • Revenue: $2.97 billion vs. $3.03 billion expected

Darden reported fiscal third-quarter net income of $312.9 million, or $2.60 per share, up from $286.6 million, or $2.34 per share, a year earlier.

Excluding items, the restaurant company earned $2.62 per share.

Net sales rose 6.8% to $2.97 billion, fueled by Darden’s acquisition of Ruth’s Chris Steak House and 53 other new restaurant locations.

But Darden’s overall same-store sales fell 1% in the quarter as almost all of its restaurant segments reported same-store sales declines. Only LongHorn Steakhouse saw same-store sales growth. A year earlier, Darden reported same-store sales growth of 11.7%.

Olive Garden, usually the crown jewel of Darden’s portfolio, reported its same-store sales fell 1.8%. Analysts were expecting the chain’s same-store sales to rise 1.3%, according to StreetAccount estimates.

LongHorn Steakhouse’s same-store sales rose 2.3%, but still fell short of StreetAccount estimates of 3.1%.

Darden’s fine-dining business, which includes The Capital Grille, saw its same-store sales decline 2.3%. That division now includes Ruth’s Chris, but those same-store results won’t be included in the category total for several more quarters.

Remaining chains, like Cheddar’s Scratch Kitchen, collectively saw same-store sales fall 2.6%.

Darden also updated its outlook for fiscal 2024. The company now expects adjusted earnings per share of $8.80 to $8.90, narrowing its earnings forecast from a prior range of $8.75 to $8.90. Darden also lowered its revenue projection from $11.5 billion to $11.4 billion and changed its same-store sales outlook from a range of 2.5% to 3% growth to a range of 1.5% to 2%.



Source

Sen. Warren blasts CFPB director for undermining Trump’s credit card affordability push
Business

Sen. Warren blasts CFPB director for undermining Trump’s credit card affordability push

U.S. Senator Elizabeth Warren (D-MA) and Director of the United States Office of Management and Budget, Russell Vought. Kevin Mohatt | Kevin Lamarque | | Reuters Sen. Elizabeth Warren on Friday accused the acting head of the Consumer Financial Protection Bureau of undermining President Donald Trump’s stated push to make credit cards more affordable, according […]

Read More
Why a niche category of CRE lending is suddenly seeing record deals
Business

Why a niche category of CRE lending is suddenly seeing record deals

Wepro | Moment | Getty Images A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight […]

Read More
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
Business

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone.  Top executives from drugmakers big and small told CNBC that the next phase […]

Read More